Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.

Haematologica - 1 Dec 2009

Jädersten Martin, Saft Leonie, Pellagatti Andrea, Göhring Gudrun, Wainscoat James S, Boultwood Jacqueline, Porwit Anna, Schlegelberger Brigitte, Hellström-Lindberg Eva

Abstract excerpt

Clonal heterogeneity has not been described in patients with myelodysplastic syndrome with isolated del(5q), for which lenalidomide has emerged as a highly potent treatment. However, transformation to acute myeloid leukemia is occasionally observed, particularly in patients without a cytogenetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Cells
Share to Chromosome Banding

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 5

Share to Clone Cells

Share to Genetic Heterogeneity

Share to Lenalidomide

Share to Myelodysplastic Syndromes

Share to Thalidomide

Source

Open in PubMed Open full text

Identifiers

PMID: 19797731
DOI: 10.3324/haematol.2009.011528
PMCID: PMC2791931

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-19797731-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.PMID 19797731Read ↗

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.Semantic proximity Read ↗

Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).Semantic proximity Read ↗

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.Semantic proximity Read ↗

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.Semantic proximity Read ↗

Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.Semantic proximity Read ↗

A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discoverySemantic proximity Read ↗

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).Semantic proximity Read ↗

Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome.Semantic proximity Read ↗

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.Semantic proximity Read ↗

Persistent malignant stem cells in del(5q) myelodysplasia in remission.Semantic proximity Read ↗

Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid MalignanciesSemantic proximity Read ↗

Single cell profiling of del(5q) MDS unveils its transcriptional landscape and the impact of lenalidomideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.